dysplasia

(redirected from bronchopulmonary dysplasia)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.

dysplasia

[di′splā·zhə]
(pathology)
Abnormal development or growth, especially of cells.
References in periodicals archive ?
Clara cell secretory protein oxidation and expression in premature infants who develop bronchopulmonary dysplasia.
Coagulase-negative staphylococcal sepsis as a predictor of bronchopulmonary dysplasia.
A review of the Bronchopulmonary Dysplasia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Drug Profiles discussed in this report include AT-100, CG-100, nitric oxide, Pneumostem, R-190, R-908, small Molecules for Bronchopulmonary Dysplasia, SX-682.
Detection of microorganisms in the tracheal aspirates of preterm infants by polymerase chain reaction: association of adenovirus infection with bronchopulmonary dysplasia.
Identification of novel Six1 functions in controlling self-renewal and maintaining lung stem cells will likely be instrumental in identifying a cure for congenital lung hypoplasia and bronchopulmonary dysplasia, conditions characterized by a significant deficiency of stem cells.
A "composite morbidity" end point was defined as the presence of one or more of these complications: bronchopulmonary dysplasia, respiratory distress syndrome, use of surfactant, necrotizing enterocolitis, retinopathy of prematurity, intraventricular hemorrhage, disseminated intravascular coagulation, and culture-proven sepsis.
The safety and efficacy of Synagis were established in infants with bronchopulmonary dysplasia (BPD), infants with a history of prematurity (less than or equal to 35 weeks gestational age), and children with hemodynamically significant congenital heart disease.
A recent study has demonstrated that for very low-birth-weight preterm infants in the NICU, human breast milk decreases the incidence of diseases such as necrotizing enterocolitis (NEC), bronchopulmonary dysplasia (BPD), and sepsis2.
Hospitalization is decreased by 55% for infants treated with palivizumab who were born prematurely at less than 36 weeks gestation who have chronic lung disease or bronchopulmonary dysplasia, and is decreased by 80%, for those born between 32-35 weeks' gestation.
In the current study, the primary composite outcome of mortality, severe respiratory distress syndrome, grade 3-4 intraventricular hemorrhage, periventricular leukomalacia, bronchopulmonary dysplasia, or necrotizing enterocolitis was similar between infants born to women who received multiple courses of corticosteroids (12.